An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma
NTC-001
Phase 1 other active
Quick answer
An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma for Metastatic melanoma is a Phase 1 program (other) at BioNTech Manufacturing GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BioNTech Manufacturing GmbH
- Indication
- Metastatic melanoma
- Phase
- Phase 1
- Modality
- other
- Status
- active